Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis a inactivated virus vaccine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hepatitis A inactivated virus vaccine is an injectable biologic used for active immunization against infection caused by the hepatitis A virus (HAV). The vaccine contains purified, formaldehyde-inactivated HAV grown in cell culture and adsorbed to aluminum hydroxide as an adjuvant. It stimulates the immune system to produce anti-HAV antibodies and memory cells by activating B and T lymphocytes upon exposure to the viral antigen. This confers long-term protection against clinical disease caused by HAV. The primary indication is prevention of hepatitis A infection; it is recommended for both pre-exposure prophylaxis (routine immunization) and post-exposure prophylaxis. Major brands include HAVRIX (developed by GSK), VAQTA (developed by Merck), and AVAXIM (developed by Sanofi). The standard regimen consists of two doses administered at least 6 months apart[1][3][5][6][8].
- Brand names
- HAVRIXVAQTAAVAXIM
- Other names
- hepatitis a vaccineinactivated hepatitis a vaccineinactivated hepatitis a virus vaccine
02
Targets
Hepatitis A virus capsid protein
Beyond the preview
Go deeper on hepatitis a inactivated virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis a inactivated virus vaccine.